Remibrutinib, an oral, highly selective Bruton’s tyrosine kinase (BTK) inhibitor, is mainly used to treat chronic spontaneous urticaria (CSU) in adults. It is approved for patients whose symptoms (hives and itching) are not adequately controlled by second-generation H1-antihistamines. It is grouped under the following drug class(es): Antineoplastic agents and Tyrosine Kinase Inhibitors. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Rhapsido (TN). Its PubChem CID is 118107483.
Remibrutinib
| CAS No | 1787294-07-8 |
|---|---|
| Molecular Formula | C27H27F2N5O3 |
| Molecular Weight | 507.5 g/mol |
| Synonyms | N-[3-[6-amino-5-[2-[methyl(prop-2-enoyl)amino]ethoxy]pyrimidin-4-yl]-5-fluoro-2-methylphenyl]-4-cyclopropyl-2-fluorobenzamide |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Remibrutinib, an oral, highly selective Bruton's tyrosine kinase (BTK) inhibitor, is mainly used to treat chronic spontaneous urticaria (CSU) in adults. It is approved for patients whose symptoms (hives and itching) are not adequately controlled by second-generation H1-antihistamines.
The listed CAS number is 1787294-07-8.
The listed molecular formula is C27H27F2N5O3.
The listed molecular weight is 507.5 g/mol.
N-[3-[6-amino-5-[2-[methyl(prop-2-enoyl)amino]ethoxy]pyrimidin-4-yl]-5-fluoro-2-methylphenyl]-4-cyclopropyl-2-fluorobenzamide.
The source lists Rhapsido (TN).